Metabolism of amylobarbitone in patients with chronic liver disease
Open Access
- 1 March 1972
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 44 (3), 549-560
- https://doi.org/10.1111/j.1476-5381.1972.tb07292.x
Abstract
1 A single dose of amylobarbitone (3·23 mg/kg) was given by intravenous injection to each of ten healthy controls and two groups of five patients with chronic liver disease. A curve of serum amylobarbitone concentration against time was prepared for each subject and the proportion of the serum amylobarbitone bound to protein determined. The urinary excretion of the metabolite hydroxyamylobarbitone, ethyl (3 hydroxyisoamyl) barbituric acid was measured. 2 The degree of protein binding of serum amylobarbitone was reduced in the five patients (group I) with abnormally low concentrations of albumin in serum (3·5 g/100 ml). 3 The equation for a double exponential decay was fitted to the concentration/time curves for amylobarbitone free in the serum water. The mean intercepts and rate constants were used to calculate the dimensions of mathematical models based on a two compartment open system. 4 The five patients (group I) who had abnormally low concentrations of albumin in serum showed impairment of amylobarbitone metabolism; the rate constant β(h−1) for the second exponential decay of serum amylobarbitone concentration was reduced (PPCe ml/min) representing amylobarbitone elimination by metabolism was reduced. 5 The five patients (group II) who had normal concentrations of albumin in serum showed no impairment of amylobarbitone metabolism. Within the total patient group there were strong and significant positive correlations between the serum albumin concentration and each of the indices of the rate of amylobarbitone metabolism. 6 Both patient groups showed an increase in the first dispositional rate constant α(h−1) and in the clearance (Ct ml/min) representing transfer between central and peripheral compartments. The physiological basis for this observation is uncertain. 7 The clinical response to the single intravenous dose of amylobarbitone was not significantly greater (P=0·11) in the patient group (I) with slow amylobarbitone metabolism than in the patient group (II) with a normal rate of amylobarbitone metabolism.Keywords
This publication has 31 references indexed in Scilit:
- PHENYLBUTAZONE AND ISONIAZID METABOLISM IN PATIENTS WITH LIVER DISEASE IN RELATION TO PREVIOUS DRUG THERAPYThe Lancet, 1968
- Shortcomings in Pharmacokinetic Analysis by Conceiving the Body to Exhibit Properties of a Single CompartmentJournal of Pharmaceutical Sciences, 1968
- Simple ultrafiltration apparatus.Journal of Clinical Pathology, 1967
- Metabolic Fate of Drugs: Barbiturates and Closely Related CompoundsAnnual Review of Pharmacology, 1967
- The metabolism of drugs by subfractions of hepatic microsomesBiochemical and Biophysical Research Communications, 1961
- HEPATIC WEDGE PRESSURE, BLOOD FLOW, VASCULAR RESISTANCE AND OXYGEN CONSUMPTION IN CIRRHOSIS BEFORE AND AFTER END-TO-SIDE PORTACAVAL SHUNT12JCI Insight, 1958
- The Distribution in the Body and Metabolic Fate of BarbituratesJournal of Pharmacy and Pharmacology, 1954
- THE ROLE OF THE LIVER IN THE DETOXICATION OF THIOPENTAL (PENTOTHAL) BY MANAnesthesiology, 1949
- INFLUENCE OF THE LIVER AND THE KIDNEY ON THE DURATION OF ANESTHESIA PRODUCED BY BARBITURATESAnesthesiology, 1945
- THE ROLE OF THE LIVER AND THE KIDNEYS FROM THE STANDPOINT OF THE ANESTHETISTAnesthesiology, 1940